Compositions And Methods For Increasing Insulin Sensitivity

Abstract

Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.

1 - 30 . (canceled) 
     
     
         31 . A method of treating a patient with a blood-glucose condition, the method comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of bupropion, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of naltrexone, or a pharmaceutically acceptable salt thereof. 
     
     
         32 . The method of  claim 31 , wherein the amount of the bupropion or a pharmaceutically acceptable salt thereof is about 200 mg per day to about 400 mg per day. 
     
     
         33 . The method of  claim 31 , wherein the amount of the naltrexone or a pharmaceutically acceptable salt thereof is about 25 mg per day to about 50 mg per day. 
     
     
         34 . The method of  claim 31 , wherein the amount of the naltrexone or pharmaceutically acceptable salt thereof is about 25 mg per day to about 38 mg per day, and wherein the amount of the bupropion or pharmaceutically acceptable salt thereof is about 300 mg per day to about 400 mg per day. 
     
     
         35 . The method of  claim 31 , wherein the blood-glucose condition is selected from diabetes, insulin resistance, hyperinsulinemia, impaired glucose metabolism, and hyperglycemia. 
     
     
         36 . The method of  claim 32 , wherein the blood-glucose condition is Type 2 diabetes. 
     
     
         37 . The method of  claim 31 , wherein the patient is obese. 
     
     
         38 . The method of  claim 31 , wherein the patient is prediabetic. 
     
     
         39 . The method of  claim 31 , further comprising obtaining a measurement of the subject's blood glucose level. 
     
     
         40 . The method of  claim 39 , further comprising adjusting a dosage of the composition after obtaining the measurement of the subject's blood glucose level. 
     
     
         41 . The method of  claim 31 , further comprising providing dietary instructions to the subject. 
     
     
         42 . The method of  claim 31 , wherein the bupropion or pharmaceutically acceptable salt thereof is administered to the subject separately from the naltrexone or pharmaceutically acceptable salt thereof. 
     
     
         43 . The method of  claim 31 , wherein the amount of bupropion or pharmaceutically acceptable salt thereof is in a divided dose for administration twice a day, and wherein the amount of naltrexone or pharmaceutically acceptable salt thereof is in a divided dose for administration twice a day. 
     
     
         44 . The method of  claim 31 , wherein the composition comprises a controlled release formulation. 
     
     
         45 . The method of  claim 43 , wherein at least one of the naltrexone or pharmaceutically acceptable salt thereof and the bupropion or pharmaceutically acceptable salt thereof is in a sustained release formulation. 
     
     
         46 . The method of  claim 44 , wherein each of the naltrexone or pharmaceutically acceptable salt thereof and the bupropion or pharmaceutically acceptable salt thereof is in a sustained release formulation. 
     
     
         47 . The method of  claim 31 , wherein the naltrexone or pharmaceutically acceptable salt thereof and the bupropion or pharmaceutically acceptable salt thereof are in a single oral dosage form. 
     
     
         48 . The method of  claim 46 , wherein the single oral dosage form is in the form of a tablet, pill, or capsule.